Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs RLX Technology Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while RLX Technology Inc trades at $1.7 (market cap $2.09B). The key difference: RLX Technology Inc is far larger — about 2.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and RLX Technology Inc pays a 5.85% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and RLX Technology Inc for 36 Days on average.
| MRVI | RLX | |
|---|---|---|
Market Cap | $972.90M | $2.09B |
Volume | 4,325,710 | 969,724 |
Sector | Health | Consumer Staples |
52-Week High | $9.00 | $2.57 |
52-Week Low | $2.83 | $1.68 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $1.08B | $817.70M |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
RLX Technology trades at $1.71, down 0.58% with bearish technical signals. The stock recently hit 52-week lows despite solid fundamentals including $3.62B revenue and 21.87% net margin. Recent earnings missed expectations but international expansion shows growth potential. Technical indicators show selling pressure with bearish moving averages.
RLX presents a value opportunity with discounted valuation (P/E 15.34, P/B 0.9) but faces execution risks. The bearish technical trend and earnings misses offset strong cash flow and international growth. Investors should weigh the discounted valuation against recent price weakness and margin compression concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
